HKMPY News and Press, Hikma Pharmaceuticals Plc ADR From 03/29/23

2023-03-29 06:05:32 ET Shanghai Junshi Biosciences ( OTCPK:SHJBF ) is collaborating with Rxilient Biotech to develop and sell cancer drug toripalimab through a joint venture, Excellmab, in nine Southeast Asian nations. Under the agreement, Rxilient will subscribe ...

2023-03-09 09:04:51 ET Hikma Pharmaceuticals ( OTCPK:HKMPY ) ( OTCPK:HKMPF ) said it launched four new sterile injectable drugs in Canada. The company added that all of the drugs, which will be launched soon, represent the first or second generic versions of their mol...

Hikma expands impact in Canada with launches of new sterile injectable medicines Canada NewsWire Builds on company's growing position in Canadian sterile injectables market LONDON , March 9, 2023 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma), the multination...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q4 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q4 - Results - Earnings Call Presentation

Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 A.M. ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Chief Executive Officer Brian Hoffmann - President of Generics Riad Mis...

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today ann...

London-based Hikma Pharmaceuticals ( OTCPK:HKMPY ) said it launched nasal spray Ryaltris for allergic rhinitis in the U.S. Hikma, a unit of  Indian drugmaker Glenmark Pharmaceuticals, noted that  Ryaltris (olopatadine hydrochloride and mometasone furoate nas...

Hikma Pharmaceuticals Plc. (HKMPF) 2022 Interim Results August 04, 2022 05:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants Presentation Said Darwazah Hello everyo...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q2 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Canada NewsWire LONDON , April 29, 2022 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary ...